Global deaths from AIDS have dropped to their lowest levels in more than 30 years, but US funding cuts could soon reverse that progress.

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and Rwanda could be among the first to deploy it, government and World Health ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

Up to six million new HIV infections and four million AIDS-related deaths could occur between 2025 and 2029 if vital ...

The UNAIDS annual report warns that Trump-era HIV funding cuts could lead to 6 million more infections and 4 million deaths ...